A research group led by Raphael Mechoulam at

Hebrew University The Hebrew University of Jerusalem (HUJI; ) is an Israeli public research university based in Jerusalem. Co-founded by Albert Einstein and Chaim Weizmann in July 1918, the public university officially opened on 1 April 1925. It is the second-ol ...

has synthesized many cannabinoids. Some of those are: *

HU-210 HU-210 is a synthetic cannabinoid that was first synthesized in 1988 from (1''R'',5''S'')- myrtenol by a group led by Raphael Mechoulam at the Hebrew University. HU-210 is 100 to 800 times more potent than natural THC from cannabis and has an ...

— a high affinity CB₁ agonist (''K''_i = 0.23 nM) *

HU-211 Dexanabinol (HU-211 or ETS2101) is a synthetic cannabinoid derivative in development by e-Therapeutics plc. It is the "unnatural" enantiomer of the potent cannabinoid agonist HU-210. Unlike other cannabinoid derivatives, HU-211 does not act as a ...

— the (+)-enantiomer of

with dramatically reduced CB₁ affinity * HU-239 — also known as

ajulemic acid Lenabasum (also known as ajulemic acid, 1',1'-dimethylheptyl-delta-8-tetrahydrocannabinol-11-oic acid, DMH-D8-THC-11-OIC, AB-III-56, HU-239, IP-751, CPL 7075, CT-3, JBT-101, Anabasum, and Resunab) is a synthetic cannabinoid that shows anti-fibro ...

* HU-243 * HU-308 *

HU-320 HU-320 (7-nor-7-carboxy-CBD-1,1-DMH) is a drug related to cannabidiol, which has strong antiinflammatory and immunosuppressive properties while demonstrating no psychoactive effects. See also * 7-Hydroxycannabidiol * Ajulemic acid * HU-210 * HU- ...

HU-331 HU-331 is a quinone anticarcinogenic drug synthesized from cannabidiol, a cannabinoid in the ''Cannabis sativa'' plant. It showed a great efficacy against oncogenic human cells. HU-331 does not cause arrest in cell cycle, cell apoptosis or casp ...

* HU-336 * HU-345